Tuesday, June 28, 2022
name of Prensa Latina
Bandera inglesa
English Edition
name of Prensa Latina



Colombia authorizes to use Cuba´s CIMAher anti-cancer drug


Colombia authorizes to use Cuba´s CIMAher anti-cancer drug

Havana, Dec 29 (Prensa Latina) Colombia´s Health and Protection Minister has authorized the inclusion of Cuba´s monoclonal antibody nimotuzumab (CIMAher) in its Domestic Benefit Plan, an official source reported Wednesday.
Share on facebook
Share on twitter
Share on whatsapp
Share on telegram
Share on email

This decision allows Colombian doctors to prescribe the brand-new drug, Cuba´s Business Group of the Biotechnology and Pharmaceutical Industries (BioCubaFarma, in Spanish) posted on Twitter.

The monoclonal antibody nimotuzumab (CIMAher), developed and produced by the Center for Molecular Immunology (CIM, in Spanish), is registered as a combination therapy with radiation therapy or chemotherapy to fight advanced-stage squamous cell cancer of head and neck.

The new product can be also prescribed for patients suffering from Gioblastoma multiforme and astrocytoma, children with high-grade glioma, esophageal, advanced non-small cell lung and locally advanced pancreatic cancer.

Since 2002, CIMAher has been registered in Cuba for being used in separate clinical trials in several nations, by guaranteeing its effectiveness and safety.


name of Prensa Latina

| Text SMS to 8100 with content PL
Receive 4 mesages x 25 cup

© 2016-2021 Prensa Latina
Latin American News Agency

Radio – Publications  – Videos – News by the minute.
All Rigts Reserved.

St. E No 454 , Vedado,  Habana, Cuba.
Phones: (+53) 7 838 3496, (+53) 7 838 3497, (+53) 7 838 3498, (+53) 7 838 3499
Prensa Latina © 2021 .

Web Site developed by IT Division  Prensa Latina.